GeneDx Holdings
WGS
GeneDx Holdings (WGS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.01
- EPS estimate
- −$0.19
- EPS surprise
- +105.32%
- Revenue surprise
- +3.09%
- Revenue
- $114.4M
- Revenue estimate
- $111.0M
- Reported
- Aug 3, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | −$0.19 | $0.01 | +105.32% | $114.4M | SEC |
| Q1 2026 | May 4, 2026 | −$0.02 | −$0.28 | −1766.67% | $102.3M | SEC |
| Q4 2025 | Feb 23, 2026 | $0.12 | $0.14 | +16.86% | $121.0M | SEC |
| Q3 2025 | Oct 28, 2025 | $0.42 | $0.49 | +15.87% | $116.7M | SEC |
| Q2 2025 | Jul 29, 2025 | $0.12 | $0.50 | +331.78% | $102.7M | SEC |
| Q1 2025 | Apr 30, 2025 | $0.06 | $0.28 | +365.65% | $87.1M | SEC |
| Q4 2024 | Feb 18, 2025 | $0.16 | $0.77 | +372.67% | $95.6M | SEC |
| Q3 2024 | Oct 29, 2024 | −$0.22 | $0.04 | +118.65% | $76.6M | SEC |
| Q2 2024 | Jul 30, 2024 | −$0.30 | −$0.11 | +64.37% | $70.5M | SEC |
| Q1 2024 | Apr 29, 2024 | −$0.67 | −$0.33 | +50.58% | $62.4M | SEC |
| Q4 2023 | Feb 20, 2024 | −$0.65 | −$0.49 | +24.87% | $58.1M | SEC |
| Q3 2023 | Oct 30, 2023 | −$1.31 | −$0.82 | +37.37% | $53.3M | SEC |
| Q2 2023 | Aug 8, 2023 | −$1.31 | −$1.65 | −25.51% | $48.7M | SEC |
| Q1 2023 | May 9, 2023 | −$1.57 | −$2.44 | −54.91% | $43.1M | SEC |
| Q4 2022 | Mar 14, 2023 | −$6.08 | −$29.70 | −388.13% | $61.4M | SEC |
| Q3 2022 | Nov 14, 2022 | −$6.82 | −$6.65 | +2.42% | $83.2M | SEC |
| Q2 2022 | Aug 15, 2022 | −$6.77 | −$7.13 | −5.34% | $36.2M | SEC |
| Q1 2022 | May 12, 2022 | −$10.56 | −$10.23 | +3.13% | $53.9M | SEC |
| Q4 2021 | Mar 14, 2022 | −$8.50 | −$5.61 | +34.00% | $57.8M | SEC |
| Q3 2021 | Nov 15, 2021 | −$6.16 | $4.95 | +180.36% | $43.2M | SEC |
Quarterly revenue
Frequently asked questions
When did GeneDx Holdings (WGS) last report earnings?
GeneDx Holdings last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did WGS beat earnings estimates?
Yes. GeneDx Holdings reported EPS of $0.01 for Q2 2026 against a −$0.19 estimate — a 105.32% beat.
How much revenue did WGS report last quarter?
GeneDx Holdings reported $114.4M in revenue for Q2 2026, against a consensus estimate of $111.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.